News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement
|Articles|October 6, 2011 (Updated: November 15, 2020)

UPS Survey Unveils Healthcare Supply Chain Trends

UPS Survey Unveils Healthcare Supply Chain Trends

Advertisement

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
Stock.adobe.com

Pharmaceutical Executive Daily: Pharma Industry's AI Adoption

ByNicholas Jacobus
March 4th 2026

AI's Inflection Point: Bridging the Adoption and ROI Gap

ByMichael Christel,Peter Young,Najat Khan, PhD
March 4th 2026
Stock.adobe.com

Antengene and UCB Enter $1.18 Billion Global License Agreement for Bispecific T-Cell Engager

ByNicholas Jacobus
March 4th 2026
Stock.adobe.com

Teva and Blackstone Life Sciences Enter $400 Million Strategic Growth Capital Agreement

ByNicholas Jacobus
March 4th 2026
Joel Stanley

FDA's History with Complex Plants

ByMike Hollan,Joel Stanley
March 4th 2026
Advertisement
Advertisement

Trending on PharmExec

1

Technological Renaissance: AI’s Integration into the Pharmaceutical Industry

2

FDA's History with Complex Plants

3

AI's Inflection Point: Bridging the Adoption and ROI Gap

4

Teva and Blackstone Life Sciences Enter $400 Million Strategic Growth Capital Agreement

5

Patent Term Extension: Challenges with Defining and Claiming Approved Biologics

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us